AstraZeneca

AstraZeneca

AstraZenecaAstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com.

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig 08 June 2017
AstraZeneca enters agreement with Recordati for Seloken in Europe 22 May 2017
AstraZeneca's potential medicine for neuromyelitis optica spectrum disorder receives orphan designation in Europe 05 April 2017
MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897 09 March 2017
Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease 24 November 2014
AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund 16 May 2014
AstraZeneca and MRC enter strategic collaboration 31 March 2014
European Commission approves Fluenz Tetra for the prevention of seasonal influenza in children 06 December 2013
Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion for the treatment of type 2 diabetes 24 November 2013
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children 24 September 2013
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre 21 March 2013
Pascal Soriot appointed Chief Executive Officer of AstraZeneca 29 August 2012
Data results of the PLATelet inhibition and patient Outcomes (PLATO) trial's health economics substudy 20 June 2012
Innovative public-private collaboration launches to tackle antibiotic research 25 May 2012
FORXIGA (dapagliflozin) receives positive CHMP opinion 20 April 2012
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe 11 January 2012
Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research 05 December 2011
KOMBOGLYZE™ receives marketing authorisation in the European Union 29 November 2011
CAPRELSA™ (vandetanib) receives positive CHMP opinion 24 November 2011
AstraZeneca to present new healthcare economics data demonstrating cost-effectiveness of BRILIQUE at ISPOR EU 21 October 2011